SG11201403935VA - Imidazopyrrolidinone compounds - Google Patents
Imidazopyrrolidinone compoundsInfo
- Publication number
- SG11201403935VA SG11201403935VA SG11201403935VA SG11201403935VA SG11201403935VA SG 11201403935V A SG11201403935V A SG 11201403935VA SG 11201403935V A SG11201403935V A SG 11201403935VA SG 11201403935V A SG11201403935V A SG 11201403935VA SG 11201403935V A SG11201403935V A SG 11201403935VA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazopyrrolidinone
- compounds
- imidazopyrrolidinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591001P | 2012-01-26 | 2012-01-26 | |
US201261669902P | 2012-07-10 | 2012-07-10 | |
CNPCT/CN2012/086703 | 2012-12-14 | ||
PCT/IB2013/050655 WO2013111105A1 (en) | 2012-01-26 | 2013-01-25 | Imidazopyrrolidinone compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201403935VA true SG11201403935VA (en) | 2014-10-30 |
Family
ID=47997596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403935VA SG11201403935VA (en) | 2012-01-26 | 2013-01-25 | Imidazopyrrolidinone compounds |
Country Status (44)
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
JP5992054B2 (en) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | Pyrazolopyrrolidine compound |
JO3357B1 (en) * | 2012-01-26 | 2019-03-13 | Novartis Ag | Imidazopyrrolidinone compounds |
JP6171003B2 (en) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | Pyrrolopyrrolidinone compounds |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
MX2015016344A (en) * | 2013-05-27 | 2016-03-01 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease. |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
EA028175B1 (en) | 2013-05-28 | 2017-10-31 | Новартис Аг | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
MX2015016425A (en) | 2013-05-28 | 2016-03-03 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease. |
EA029269B1 (en) * | 2013-11-21 | 2018-02-28 | Новартис Аг | Pyrrolopyrrolone derivatives and their use for treating diseases |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
CN105848656B (en) * | 2013-12-23 | 2019-10-25 | 诺华股份有限公司 | Pharmaceutical composition |
BR112016012506A8 (en) * | 2013-12-23 | 2018-01-30 | Novartis Ag | pharmaceutical combinations, their uses, and use of a data carrier |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CR20160425A (en) | 2014-03-14 | 2017-05-26 | Novartis Ag | ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME |
TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
ES2952717T3 (en) | 2014-10-14 | 2023-11-03 | Novartis Ag | Antibody molecules against PD-L1 and uses thereof |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN114272371A (en) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | Combination therapy comprising anti-PD-1 antibody molecules |
LT3317301T (en) | 2015-07-29 | 2021-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
TWI804010B (en) * | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | Gdf-15 as a haematological toxicity biomarker |
BR112018000496A2 (en) * | 2015-08-14 | 2018-09-11 | Novartis Ag | pharmaceutical combinations and their use |
ES2962460T3 (en) * | 2015-08-28 | 2024-03-19 | Novartis Ag | MDM2 inhibitors and combinations of these |
EP3341023A1 (en) | 2015-08-28 | 2018-07-04 | Novartis AG | Combination therapy using pi3k inhbitor and mdm2 inhibitor |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
BR112018008891A8 (en) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | antibodies that specifically bind to pd-1 and tim-3 and their uses |
EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
JP6890659B2 (en) | 2016-11-15 | 2021-06-18 | ノバルティス アーゲー | HDM2-p53 Interaction Inhibitor Dose and Regimen |
WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
WO2018096440A1 (en) * | 2016-11-22 | 2018-05-31 | Novartis Ag | Chemical process for preparing imidazopyrrolidinone derivatives and intermediates thereof |
WO2018158225A1 (en) | 2017-02-28 | 2018-09-07 | Les Laboratoires Servier | Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof |
WO2018161871A1 (en) * | 2017-03-06 | 2018-09-13 | 罗欣生物科技(上海)有限公司 | Imidazopyridine compound as p53-mdm2 inhibitor |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US20200281925A1 (en) | 2017-03-31 | 2020-09-10 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
WO2018185135A1 (en) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
UY37695A (en) | 2017-04-28 | 2018-11-30 | Novartis Ag | BIS 2’-5’-RR- (3’F-A) (3’F-A) CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
US11413284B2 (en) | 2017-09-12 | 2022-08-16 | Novartis Ag | Protein kinase C inhibitors for treatment of uveal melanoma |
EP3691616A1 (en) | 2017-10-02 | 2020-08-12 | Novartis AG | Method for preparing a pharmaceutical product |
JP7332589B2 (en) | 2017-10-12 | 2023-08-23 | ノバルティス アーゲー | Combining an MDM2 inhibitor and an inhibitor of ERK to treat cancer |
BR112020008888A2 (en) | 2017-11-16 | 2020-10-20 | Novartis Ag | combination therapies |
SG11202006262TA (en) * | 2017-12-29 | 2020-07-29 | Gan & Lee Pharmaceuticals | Compound capable of being used as tumor inhibitor, preparation method therefor, and application thereof |
EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
EP3766883B1 (en) * | 2018-03-12 | 2022-09-28 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Imidaxopyrolone compound and application thereof |
AU2019240200B2 (en) | 2018-03-20 | 2022-07-21 | Novartis Ag | Pharmaceutical combinations |
UY38247A (en) | 2018-05-30 | 2019-12-31 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
AU2019400980A1 (en) | 2018-12-20 | 2021-06-24 | Novartis Ag | Pharmaceutical combinations |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CN113227138A (en) | 2018-12-21 | 2021-08-06 | 诺华股份有限公司 | Use of IL-1 beta binding antibodies |
US20200369762A1 (en) | 2018-12-21 | 2020-11-26 | Novartis Ag | Use of il-1beta binding antibodies |
US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113329792A (en) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | Substituted 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof |
CN113631558A (en) * | 2019-04-04 | 2021-11-09 | 诺华股份有限公司 | SIREMADLIN succinic acid ester |
CN114096541B (en) * | 2019-09-12 | 2023-04-04 | 罗欣药业(上海)有限公司 | Crystal form of p53-MDM2 inhibitor and preparation method thereof |
CA3152840A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of an mdm2 inhibitor for the treatment of myelofibrosis |
JP2022548881A (en) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy |
US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP4204812A2 (en) | 2020-08-27 | 2023-07-05 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
TW202218665A (en) | 2020-09-21 | 2022-05-16 | 德國阿爾伯特路德維希弗萊堡大學 | Mdm2 inhibitors for use in the treatment or prevention of hematologic neoplasm relapse after hematopoietic cell transplantation |
GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
AR125874A1 (en) | 2021-05-18 | 2023-08-23 | Novartis Ag | COMBINATION THERAPIES |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
WO2023067483A1 (en) | 2021-10-19 | 2023-04-27 | Novartis Ag | Pharmaceutical combinations comprising an mdm2 inhibitor, a bcl2 inhibitor and a hypomethylating agent and uses thereof for the treatment of haematological malignancies |
WO2024097948A1 (en) * | 2022-11-04 | 2024-05-10 | Roivant Discovery, Inc. | Degraders of mdm2 and uses thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (en) | 1982-07-23 | 1987-08-15 | Ici Plc | AMIDE DERIVATIVES. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
DE69233803D1 (en) | 1992-10-28 | 2011-03-31 | Genentech Inc | Use of vascular endothelial growth factor antagonists |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
DE69536015D1 (en) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Quinazolinone derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
BR9609617B1 (en) | 1995-07-06 | 2010-07-27 | 7h-pyrrol [2,3-d] pyrimidine derivatives, and pharmaceutical composition. | |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
WO1997049688A1 (en) | 1996-06-24 | 1997-12-31 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
JP2001500851A (en) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | Process for producing epothilone and intermediate products obtained during the process |
EP0938597B1 (en) | 1996-09-06 | 2003-08-20 | Obducat Aktiebolag | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (en) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CN100344627C (en) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | Epothilones C, and its preparation and use as cell inhibitor |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
ES2342240T3 (en) | 1998-08-11 | 2010-07-02 | Novartis Ag | ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA. |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
KR100716272B1 (en) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
EP1140173B2 (en) | 1998-12-22 | 2013-04-03 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
BR0009507A (en) | 1999-03-30 | 2002-01-15 | Novartis Ag | Phthalazine derivatives for the treatment of inflammatory diseases |
PE20010306A1 (en) | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
BR0113176A (en) | 2000-08-10 | 2003-06-17 | Pharmacia Italia Spa | Bicyclo-pyrazole compounds, pharmaceutical compositions comprising the compounds, use of the compounds in the manufacture of medicaments, processes for the preparation of the compounds, combinatorial chemical collection and methods for the treatment of mammals including humans using the compounds. |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
AR035885A1 (en) | 2001-05-14 | 2004-07-21 | Novartis Ag | DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
DE60225719T2 (en) * | 2001-12-18 | 2009-04-23 | F. Hoffmann-La Roche Ag | CIS-2,4,5-TRIPHENYL-IMIDAZOLINE AND ITS USE IN THE TREATMENT OF TUMORS |
US20060189511A1 (en) | 2002-05-13 | 2006-08-24 | Koblish Holly K | Method for cytoprotection through mdm2 and hdm2 inhibition |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
ATE414693T1 (en) | 2004-05-18 | 2008-12-15 | Hoffmann La Roche | NOVEL CIS-IMIDAZOLINES |
KR101331786B1 (en) * | 2004-09-22 | 2013-11-21 | 얀센 파마슈티카 엔.브이. | Inhibitors of the interaction between mdm2 and p53 |
US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
US20060160869A1 (en) | 2005-01-05 | 2006-07-20 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
JP5222731B2 (en) | 2005-12-12 | 2013-06-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
WO2007096334A1 (en) | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
US8367699B2 (en) | 2006-09-15 | 2013-02-05 | Nexuspharma, Inc. | Tetrahydro-isoquinolines |
KR20100016076A (en) | 2007-03-30 | 2010-02-12 | 시오노기 앤드 컴파니, 리미티드 | Novel pyrrolinone derivative and medicinal composition containing the same |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
TW201016702A (en) | 2008-09-25 | 2010-05-01 | Shionogi & Co | Novel pyrrolinone derivative and pharmaceutical composition comprising the same |
WO2010141738A2 (en) | 2009-06-03 | 2010-12-09 | President And Fellows Of Harvard College | Compositions and method for inhibiting tumor growth |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
GB201016880D0 (en) | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
JP5992054B2 (en) * | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | Pyrazolopyrrolidine compound |
JO3357B1 (en) * | 2012-01-26 | 2019-03-13 | Novartis Ag | Imidazopyrrolidinone compounds |
JP6171003B2 (en) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | Pyrrolopyrrolidinone compounds |
-
2013
- 2013-01-24 JO JOP/2013/0025A patent/JO3357B1/en active
- 2013-01-24 US US13/748,790 patent/US8815926B2/en active Active
- 2013-01-24 UY UY0001034591A patent/UY34591A/en active IP Right Grant
- 2013-01-25 PL PL13711952T patent/PL2807164T3/en unknown
- 2013-01-25 MY MYPI2014002033A patent/MY177242A/en unknown
- 2013-01-25 CN CN201380016617.6A patent/CN104203952B/en active Active
- 2013-01-25 WO PCT/IB2013/050655 patent/WO2013111105A1/en active Application Filing
- 2013-01-25 EP EP16161001.9A patent/EP3064502A1/en not_active Withdrawn
- 2013-01-25 ES ES13711952.5T patent/ES2632430T3/en active Active
- 2013-01-25 PT PT137119525T patent/PT2807164T/en unknown
- 2013-01-25 ES ES17182338T patent/ES2743962T3/en active Active
- 2013-01-25 EA EA201790134A patent/EA201790134A3/en unknown
- 2013-01-25 EP EP17182338.8A patent/EP3272754B1/en active Active
- 2013-01-25 PE PE2014001168A patent/PE20141655A1/en active IP Right Grant
- 2013-01-25 TW TW105143227A patent/TW201713644A/en unknown
- 2013-01-25 AP AP2014007810A patent/AP2014007810A0/en unknown
- 2013-01-25 BR BR112014018475-5A patent/BR112014018475B1/en active IP Right Grant
- 2013-01-25 LT LTEP13711952.5T patent/LT2807164T/en unknown
- 2013-01-25 SG SG11201403935VA patent/SG11201403935VA/en unknown
- 2013-01-25 SI SI201330691T patent/SI2807164T1/en unknown
- 2013-01-25 RS RS20170670A patent/RS56197B1/en unknown
- 2013-01-25 CU CUP2014000091A patent/CU24336B1/en unknown
- 2013-01-25 TW TW102103027A patent/TWI579284B/en active
- 2013-01-25 DK DK13711952.5T patent/DK2807164T3/en active
- 2013-01-25 GE GEAP201313535A patent/GEP20166438B/en unknown
- 2013-01-25 AU AU2013213260A patent/AU2013213260B2/en active Active
- 2013-01-25 JP JP2014553845A patent/JP5865519B2/en active Active
- 2013-01-25 AR ARP130100227A patent/AR089807A1/en active IP Right Grant
- 2013-01-25 EA EA201491423A patent/EA027130B1/en not_active IP Right Cessation
- 2013-01-25 NZ NZ627277A patent/NZ627277A/en unknown
- 2013-01-25 EP EP13711952.5A patent/EP2807164B1/en active Active
- 2013-01-25 KR KR1020167035785A patent/KR20160150292A/en not_active Application Discontinuation
- 2013-01-25 CA CA2860951A patent/CA2860951C/en active Active
- 2013-01-25 KR KR1020147023313A patent/KR101694383B1/en active IP Right Grant
- 2013-01-25 UA UAA201407720A patent/UA115231C2/en unknown
- 2013-01-25 MX MX2014009089A patent/MX353315B/en active IP Right Grant
-
2014
- 2014-07-10 US US14/327,639 patent/US20140343084A1/en not_active Abandoned
- 2014-07-14 CL CL2014001855A patent/CL2014001855A1/en unknown
- 2014-07-18 MA MA37217A patent/MA35869B1/en unknown
- 2014-07-21 IL IL233739A patent/IL233739A/en active IP Right Grant
- 2014-07-22 DO DO2014000170A patent/DOP2014000170A/en unknown
- 2014-07-22 CR CR20140354A patent/CR20140354A/en unknown
- 2014-07-23 TN TNP2014000319A patent/TN2014000319A1/en unknown
- 2014-07-24 CO CO14161419A patent/CO7010838A2/en active IP Right Grant
- 2014-07-25 NI NI201400083A patent/NI201400083A/en unknown
- 2014-07-25 GT GT201400164A patent/GT201400164A/en unknown
- 2014-07-25 PH PH12014501702A patent/PH12014501702B1/en unknown
- 2014-08-25 EC ECIEPI201415553A patent/ECSP14015553A/en unknown
- 2014-12-04 HK HK14112230.9A patent/HK1198761A1/en unknown
-
2015
- 2015-12-22 JP JP2015250003A patent/JP2016106095A/en not_active Withdrawn
-
2017
- 2017-02-23 JP JP2017031964A patent/JP2017125037A/en active Pending
- 2017-07-03 HR HRP20171005TT patent/HRP20171005T1/en unknown
- 2017-07-05 CY CY20171100717T patent/CY1119058T1/en unknown
-
2018
- 2018-04-23 HK HK18105237.2A patent/HK1245780B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268013A (en) | Tetrahydropyrazolopyrimidine compounds | |
HK1245780B (en) | Imidazopyrrolidinone compounds | |
IL237341A0 (en) | Pro-neurogenic compounds | |
GB201209138D0 (en) | Compounds | |
GB201214750D0 (en) | Compounds | |
GB201215357D0 (en) | Compounds | |
EP2887803A4 (en) | Pro-neurogenic compounds | |
HK1206726A1 (en) | Imidazotriazinone compounds | |
GB201204985D0 (en) | Compounds | |
GB201204125D0 (en) | Compounds | |
PL2836495T3 (en) | Tetrahydropyrrolothiazine compounds | |
HK1211283A1 (en) | Compounds | |
GB201209096D0 (en) | Compounds | |
GB201219820D0 (en) | Compounds | |
GB201217310D0 (en) | Compounds | |
GB201223429D0 (en) | Compounds | |
GB201219819D0 (en) | Compounds | |
GB201218799D0 (en) | Compounds | |
GB201218776D0 (en) | Compounds | |
GB201218758D0 (en) | Compounds | |
GB201218774D0 (en) | Compounds | |
GB201218018D0 (en) | Compounds | |
GB201217290D0 (en) | Compounds | |
GB201217311D0 (en) | Compounds | |
GB201217312D0 (en) | Compounds |